# Genome Engineering Shared Resource

> **NIH NIH P30** · UNIVERSITY OF MINNESOTA · 2024 · $88,273

## Abstract

Genome Engineering Shared Resource Summary
The goals of the Genome Engineering Shared Resource (GESR) are to utilize state-of-the-art CRISPR/Cas9-
mediated precise genome engineering to efficiently generate desired modifications in mammalian (most
frequently human) cells in an accurate and timely manner. This will be done through the following specific
aims: 1) To provide CRISPR/Cas9 gene editing design services coordinated with the individual researcher with
the goal of generating the desired genetic modification in their model cell line; 2) To provide CRISPR/Cas9
targeting reagents to be used by clients if they have the personnel and expertise already in place in their own
laboratory for gene-targeting experiments; 3) To use the CRISPR/Cas9 system to generate cell lines of an
investigator's choice containing a) knockouts of non-essential genes, b) conditional knockouts of essential
genes, c) knock-in mutations, or d) gene tagging; 4) To work with the Mouse Genetics Laboratory (MGL)
Shared Resource to create mutant mice using CRISPR/Cas9-mediated gene targeting; and 5) To work with the
Stem Cell Institute with the goal of offering CRISPR/Cas9 genome editing of human induced pluripotent stem
cells for researchers requiring this service.
The GESR provides Masonic Cancer Center (MCC) members with convenient, cost-effective access to these
reagents and services for genetic modification that can only rarely (or very expensively) be obtained from
commercial sources. Access to these human cell lines and associated CRISPR/Cas9 technologies is critical to
the ongoing work of the MCC, especially to members of the Genetic Mechanisms, Immunology, and Cellular
Mechanisms Programs.
Over the past 7 years, the GESR has successfully generated 61 independent knockouts of non-essential
genes, 5 conditional knockouts, 20 single-nucleotide knock-ins, and 11 gene-tagged cell lines and has assisted
MGL in the generation of 8 knockout, 12 conditional knockout, 9 knock-in, and 10 gene-tagged mouse strains.
The GESR is co-led by Drs. Branden Moriarity (Genetic Mechanisms [GM] and Transplant and Cellular
Therapy [TCT] Programs) and Dr. Beau Webber (GM and TCT). Dr. Moriarity has over 10 years of experience
in gene editing using TALENs and the CRISPR/Cas9 system. His laboratory focuses on gene editing in
primary human immune cells for research and therapy. Dr. Webber has over 6 years of experience in gene
editing. His focus is to synergize genome engineering, stem cell biology, and adoptive cellular therapy to
develop cures for genetic disease and cancer. The GESR is coordinated by Walker Lahr, who brings 7 years of
experience to GESR.
In fiscal year 2022, 32 individuals used GESR services, of whom 28 were MCC members.

## Key facts

- **NIH application ID:** 10768163
- **Project number:** 2P30CA077598-26
- **Recipient organization:** UNIVERSITY OF MINNESOTA
- **Principal Investigator:** Branden S Moriarity
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $88,273
- **Award type:** 2
- **Project period:** 1998-06-01 → 2029-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768163

## Citation

> US National Institutes of Health, RePORTER application 10768163, Genome Engineering Shared Resource (2P30CA077598-26). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10768163. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*